Phase 1 clinical trial: delNS-based immunotherapy against HPV 16

Viennese biotechnology company BlueSky Immunotherapies GmbH (Ltd.) has completed the second cohort of its phase 1 clinical trial against HPV 16.

The results: Intradermal administration has been confirmed to be safe and well tolerated. Preliminary indications of efficacy were observed. Their proprietary innovative delNS technology for interferon-inducing viral vectors is a next-generation immunotherapy against cancer and infectious diseases. A high level of interferon is induced by the delNS vector that activates immunological defence reactions against cervical cancer.

Following this, its safety and efficacy in the third cohort using intramuscular treatment will be assessed.